Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 573

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 573
---
 January 2025. •Amendment to IAS 7 and IFRS 7 — Supplier Financing. The amendments are effective for annual periods beginning on or after January1, 2024. F-73 Notes to Combined Financial Statements (Amounts in US Dollars, except otherwise indicated) 2.Summary of significant accounting policies and basis of preparation (cont.) These standards and amendments are not expected to have a material impact on the Group: •IFRS 18 — Presentation and Disclosure in Financial Statements. This standard sets out requirements for the presentation and disclosure of information in general purpose financial statements to help ensure they provide relevant information that faithfully represents an entity’s assets, liabilities, equity, income and expenses. It is effective for annual periods beginning on or after January1, 2027 •Amendments to IFRS 9 and IFRS 7 — Amendments to the Classification and Measurement of Financial Instruments. The amendments are effective for reporting periods beginning on or after 1 January 2026. The Group is currently analyzing the potential impact of these new standards on our financial statements. 2.3Foreign currency Foreign currency transactions are translated into the functional currency of the Company using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year -endexchange rates of monetary assets and liabilities nominated in foreign currencies are recognized in the profit or loss for the year. Foreign exchange gains and losses are presented in the statement of operations within other financial income, as appropriate, unless they have been capitalized. 2.4Revenue recognition The Group operates through two operating segments, Rewell and Heritas Diagnostics. The Group recognizes revenue when control of the services are fully delivered to customers when performance obligations are met. This is recognized at an amount that reflects the consideration to which the Group expects to receive in exchange for transferring these services to customers (the “Transaction Price”). Heritas Diagnostics Segment Revenues from the Group’s Heritas Diagnostics segment are typically generated from genetic sequencing and diagnostics services covering the fields of oncology, prenatal care, rare diseases and clinical gut health, and provides other genetic sequencing services. The Group has entered into a commercial partnership with Cibic — Centro de Diagnóstico Medico de Alta Complejidad S.A. (“CIBIC”), a shareholder of OminigenicsAI Corp., for the purpose of providing these clinical genetic tests. Under this partnership agreement, CIBIC exclusively handles the commercialization of all Heritas